We have a Large Staff of Former FDA & Industry Experts
Ranked #294 on 2015 List - #7 for Massachusetts
Free Webinar:
Laboratory Developed Tests: Issues and Anticipated Regulations

You are invited to join us for a webinar. Please click here to learn more.

Blog & Updates

In 2002, FDA launched an initiative entitled, “Pharmaceutical cGMPs for the 21st Century: A Risk-Based Approach” to encourage the implementation of a modern, risk-based pharmaceutical quality assessment system. In an effort to support that initiative, FDA released a draft guidance document titled “Request for Quality Metrics: Guidance for Industry” in July of 2015. This draft […]

Continue Reading

On August 27, 2015, the Food and Drug Administration issued a guidance that establishes a naming convention for biologicals. Included among these biologicals are biosimilar products. The issuing of this guidance serves to resolve debates on how such compounds should be named. According to the guidance, biosimilar products will share the same nonproprietary name as […]

Continue Reading

September 18, 2015

The FDA and Nanotechnology

Nanotechnology is one of the newest areas in the pharmaceutical industry. Although nanotechnology has shown promise in increasing the bioavailability of pharmaceuticals, the clarity of radiographic procedures, and the effectiveness of targeted therapies, the Food and Drug Administration considers the changes in the products manufactured with nanotechnology to be in need of further assessment to […]

Continue Reading

Personalized medicine has attracted much interest within the healthcare community during recent years. More physicians are striving to customize their medical treatments to their patients’ unique genetic makeup and circumstances. However, personalized medicine poses a number of regulatory challenges. As such, pharmaceutical executives should understand these challenges and how they affect the industry. What Is […]

Continue Reading

In addition to approving pharmaceuticals and biologics, the Food and Drug Administration is responsible for determining whether an approved treatment is safe. As such, they require the companies that manufacture these treatments to report on adverse events that patients experience after a treatment is approved. Pharmaceutical companies should understand the appropriate mechanisms to submit these […]

Continue Reading


The owner of TheFDAGroup.com will not be liable for any errors or omissions in this information nor for the availability of this information. The owner will not be liable for any losses, injuries, or damages from the display or use of this information.